124 related articles for article (PubMed ID: 10584838)
1. Apoptotic elimination of peripheral T lymphocytes in patients with primary intracranial tumors.
Morford LA; Dix AR; Brooks WH; Roszman TL
J Neurosurg; 1999 Dec; 91(6):935-46. PubMed ID: 10584838
[TBL] [Abstract][Full Text] [Related]
2. In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect.
McVicar DW; Davis DF; Merchant RE
J Neurosurg; 1992 Feb; 76(2):251-60. PubMed ID: 1730954
[TBL] [Abstract][Full Text] [Related]
3. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro.
Hishii M; Nitta T; Ishida H; Ebato M; Kurosu A; Yagita H; Sato K; Okumura K
Neurosurgery; 1995 Dec; 37(6):1160-6; discussion 1166-7. PubMed ID: 8584157
[TBL] [Abstract][Full Text] [Related]
4. Similar immunity profiles in patients with meningioma and glioma tumors despite differences in the apoptosis and necrosis of circulating lymphocyte and monocyte populations.
Kataki A; Skandami V; Memos N; Nikolopoulou M; Oikonomou V; Androulis A; Konstadoulakis MM; Zografos CG
J Neurosurg Sci; 2014 Mar; 58(1):9-15. PubMed ID: 24614787
[TBL] [Abstract][Full Text] [Related]
5. Modulation of T-cell function by gliomas.
Roszman T; Elliott L; Brooks W
Immunol Today; 1991 Oct; 12(10):370-4. PubMed ID: 1958290
[TBL] [Abstract][Full Text] [Related]
6. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers.
Zou JP; Morford LA; Chougnet C; Dix AR; Brooks AG; Torres N; Shuman JD; Coligan JE; Brooks WH; Roszman TL; Shearer GM
J Immunol; 1999 Apr; 162(8):4882-92. PubMed ID: 10202033
[TBL] [Abstract][Full Text] [Related]
7. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
8. Immune defects observed in patients with primary malignant brain tumors.
Dix AR; Brooks WH; Roszman TL; Morford LA
J Neuroimmunol; 1999 Dec; 100(1-2):216-32. PubMed ID: 10695732
[TBL] [Abstract][Full Text] [Related]
9. Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals.
Landis RC; Friedman ML; Fisher RI; Ellis TM
J Immunol; 1991 Jan; 146(1):128-35. PubMed ID: 1824588
[TBL] [Abstract][Full Text] [Related]
10. The role of regulatory T-cells in glioma immunology.
Ooi YC; Tran P; Ung N; Thill K; Trang A; Fong BM; Nagasawa DT; Lim M; Yang I
Clin Neurol Neurosurg; 2014 Apr; 119():125-32. PubMed ID: 24582432
[TBL] [Abstract][Full Text] [Related]
11. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis.
Sebbag M; Parry SL; Brennan FM; Feldmann M
Eur J Immunol; 1997 Mar; 27(3):624-32. PubMed ID: 9079801
[TBL] [Abstract][Full Text] [Related]
12. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors.
Elliott LH; Brooks WH; Roszman TL
J Immunol; 1984 Mar; 132(3):1208-15. PubMed ID: 6319491
[TBL] [Abstract][Full Text] [Related]
13. Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells.
Domenis R; Cesselli D; Toffoletto B; Bourkoula E; Caponnetto F; Manini I; Beltrami AP; Ius T; Skrap M; Di Loreto C; Gri G
PLoS One; 2017; 12(1):e0169932. PubMed ID: 28107450
[TBL] [Abstract][Full Text] [Related]
14. Enhanced interleukin-1 beta release and longevity of glioma-associated peripheral blood monocytes in vitro.
Fries G; Perneczky A; Kempski O
Neurosurgery; 1994 Aug; 35(2):264-70; discussion 270-1. PubMed ID: 7969834
[TBL] [Abstract][Full Text] [Related]
15. Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients.
Spolarics Z; Siddiqi M; Siegel JH; Garcia ZC; Stein DS; Denny T; Deitch EA
Crit Care Med; 2003 Jun; 31(6):1722-9. PubMed ID: 12794411
[TBL] [Abstract][Full Text] [Related]
16. Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay.
Wendelbo Ø; Bruserud Ø
J Hematother Stem Cell Res; 2003 Oct; 12(5):525-35. PubMed ID: 14594509
[TBL] [Abstract][Full Text] [Related]
17. Human liver sinusoidal endothelial cells induce apoptosis in activated T cells: a role in tolerance induction.
Karrar A; Broomé U; Uzunel M; Qureshi AR; Sumitran-Holgersson S
Gut; 2007 Feb; 56(2):243-52. PubMed ID: 16840505
[TBL] [Abstract][Full Text] [Related]
18. Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas.
Elliott L; Brooks W; Roszman T
J Natl Cancer Inst; 1987 May; 78(5):919-22. PubMed ID: 3106694
[TBL] [Abstract][Full Text] [Related]
19. Effect of FK506 on the interleukin 15-driven proliferation and apoptosis of anti-CD3-activated umbilical cord blood T cells.
Lin SJ; Yan DC; Kuo ML; Cheng PJ; Hsiao SS; Tsai TL
Ann Allergy Asthma Immunol; 2005 Dec; 95(6):586-92. PubMed ID: 16400900
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-17 facilitates the immune suppressor capacity of high-grade glioma-derived CD4 (+) CD25 (+) Foxp3 (+) T cells via releasing transforming growth factor beta.
Liang H; Yi L; Wang X; Zhou C; Xu L
Scand J Immunol; 2014 Aug; 80(2):144-50. PubMed ID: 24813240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
